Lab
Highline Labs, LLC
Highline Labs, LLC was paid $5.72M by Medicaid between Jan 2018 and Jun 2020, across 101 billing codes. Its largest line is 80307, Drug test(s), presumptive, any number of drug classes; immunoassay — 22% of everything it billed.
33Billing provider infoHIGHLINE LABS, LLC
CHARLOTTE, NC 28269
CHARLOTTE, NC 28269
33aNPI1639541295assigned 10/22/2015
33bProvider typeClinical Medical Laboratory
28Total paid$5.72M
24GClaims237,630
24DCodes billed101
24AFirst – last monthJan 2018 – Jun 2020
Compared with peers
Next to other Clinical Medical Laboratory providers in North Carolina
Rank by total paid#18 of 128
Median peer was paid$268K
This provider vs. median21×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 93,519 | $2.31M | |
| 2019 | 129,873 | $3.00M | |
| 2020 | 14,238 | $420K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 22% | 40,410 | 31,471 | $1.23M |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 18% | 16,114 | 12,861 | $1.05M |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 13% | 10,129 | 8,318 | $716K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 7.7% | 7,276 | 6,027 | $438K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 3.6% | 4,597 | 2,458 | $206K |
| 81226 | 2.2% | 1,537 | 1,389 | $127K | |
| 81225 | 1.4% | 1,522 | 1,371 | $83K | |
| 80346 | 1.4% | 6,118 | 5,194 | $80K | |
| 80361 | 1.4% | 6,152 | 5,217 | $79K | |
| 80348 | 1.4% | 6,133 | 5,193 | $78K | |
| 80356 | 1.4% | 6,056 | 5,133 | $78K | |
| 80365 | 1.3% | 6,150 | 5,215 | $77K |
89 more codes
| 80353 | 1.3% | 6,319 | $76K | |
| 80354 | 1.3% | 5,988 | $76K | |
| 80359 | 1.3% | 5,836 | $74K | |
| 80325 | 1.3% | 5,802 | $72K | |
| 83992 | 1.3% | 5,187 | $72K | |
| 80373 | 1.2% | 5,602 | $69K | |
| 80358 | 1.2% | 5,304 | $68K | |
| 80360 | 1.1% | 5,296 | $65K | |
| 80372 | 1.1% | 5,311 | $65K | |
| 80363 | <1% | 4,195 | $53K | |
| 81227 | <1% | 1,524 | $51K | |
| 80349 | <1% | 4,238 | $50K | |
| 80345 | <1% | 3,215 | $39K | |
| 81401 | <1% | 1,828 | $32K | |
| 80357 | <1% | 2,333 | $31K | |
| 80323 | <1% | 2,127 | $31K | |
| 80370 | <1% | 1,807 | $28K | |
| 81241 | <1% | 1,418 | $26K | |
| 80320 | <1% | 2,002 | $25K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,309 | $25K |
| 80355 | <1% | 2,618 | $25K | |
| 80366 | <1% | 2,558 | $24K | |
| 80364 | <1% | 1,834 | $23K | |
| 81328 | <1% | 1,007 | $23K | |
| 81240 | <1% | 1,418 | $22K | |
| 81230 | <1% | 1,094 | $20K | |
| 81231 | <1% | 1,090 | $20K | |
| 80050 | General health panel | <1% | 559 | $18K |
| 81291 | <1% | 1,415 | $17K | |
| 81355 | <1% | 1,311 | $15K | |
| 84481 | <1% | 1,214 | $14K | |
| 80061 | Lipid panel | <1% | 1,536 | $14K |
| 84403 | <1% | 730 | $13K | |
| 82607 | <1% | 1,176 | $12K | |
| 82670 | <1% | 577 | $12K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 995 | $11K |
| 82627 | <1% | 621 | $11K | |
| 86376 | <1% | 1,037 | $10K | |
| 80053 | Comprehensive metabolic panel | <1% | 1,510 | $10K |
| 83970 | <1% | 340 | $9K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,265 | $8K |
| 82728 | <1% | 752 | $8K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 55 | $7K |
| 84270 | <1% | 540 | $7K | |
| 84439 | <1% | 1,190 | $7K | |
| 84144 | <1% | 522 | $7K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 1,230 | $6K |
| 82172 | <1% | 382 | $5K | |
| 83001 | <1% | 510 | $5K | |
| 81400 | <1% | 226 | $5K | |
| 82533 | <1% | 404 | $5K | |
| 82746 | <1% | 440 | $5K | |
| 83002 | <1% | 481 | $4K | |
| 84681 | <1% | 224 | $4K | |
| 83735 | <1% | 826 | $4K | |
| 83003 | <1% | 361 | $4K | |
| 83090 | <1% | 280 | $4K | |
| 83550 | <1% | 576 | $3K | |
| 86141 | <1% | 240 | $3K | |
| 83525 | <1% | 265 | $3K | |
| 84146 | <1% | 203 | $3K | |
| 83540 | <1% | 520 | $2K | |
| 83695 | <1% | 274 | $2K | |
| 80368 | <1% | 166 | $2K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 109 | $2K |
| 80342 | <1% | 367 | $1K | |
| 84550 | <1% | 468 | $1K | |
| 87486 | <1% | 59 | $918.19 | |
| 84153 | <1% | 71 | $876.06 | |
| 87581 | <1% | 54 | $687.37 | |
| 80367 | <1% | 240 | $639.17 | |
| 81479 | Unlisted molecular pathology procedure | <1% | 9,915 | $608.95 |
| 82977 | <1% | 77 | $534.48 | |
| 86696 | <1% | 19 | $410.21 | |
| 80369 | <1% | 19 | $341.41 | |
| 86038 | <1% | 132 | $329.78 | |
| 81003 | <1% | 145 | $318.24 | |
| 86695 | <1% | 19 | $279.31 | |
| 86140 | <1% | 45 | $251.55 | |
| APT17 | <1% | 14 | $186.06 | |
| 85610 | <1% | 47 | $171.94 | |
| 86431 | <1% | 154 | $171.22 | |
| 82043 | <1% | 29 | $110.27 | |
| 80362 | <1% | 126 | $88.33 | |
| 81001 | <1% | 30 | $67.71 | |
| 80324 | <1% | 17 | $60.64 | |
| 83690 | <1% | 18 | $54.58 | |
| 84480 | <1% | 32 | $46.65 | |
| 84436 | <1% | 17 | $8.62 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDIENST, RYAN (CEO)